Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration

Date : 10/01/2018 @ 10:00AM
Source : GlobeNewswire
Stock : Immunomedics, Inc. (IMMU)
Quote : 20.21  -1.14 (-5.34%) @ 8:00PM

Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration

Press Release

1 October 2018

Immunicum AB (publ) Gives Information on Trading Halt and Ongoing Negotiations for a Potential Collaboration

Immunicum AB (publ; IMMU.ST) today announced that Nasdaq Stockholm decided to halt trading in the Company's share as a result of share price movements. Immunicum cannot assess whether these movements are related to information leakage from an ongoing negotiation for a development collaboration.

The Company therefore wishes to inform that Immunicum is in negotiations with a leading global pharmaceutical company regarding a development agreement for ilixadendel, an off the shelf cancer immune primer. It is currently not possible to assess whether these negotiations will lead to an agreement.

Under the collaboration agreement being negotiated, Immunicum expects to get access to a checkpoint inhibitor to be combined with ilixadencel in the planned Phase II study, ILIAD. The agreement will not be associated with any payments to Immunicum.

Immunicum will inform the market about the outcomes from the ongoing negotiations as soon as more specific information becomes available.

The information is such information that Immunicum is obliged to make public pursuant to EU Market Abuse Regulation. The information was released for public disclosure through the contact persons detailed below on 1 October 2018 at 4.00 pm CET.

For more information, please contact:

Carlos de Sousa, CEO, Immunicum
Telephone: +46 (0) 31 41 50 52
E-mail: info@immunicum.com 

Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com 

Media Relations

Gretchen Schweitzer and Joanne Tudorica
Trophic Communications
Telephone: +49 172 861 8540
E-mail: ir@immunicum.com

  About Immunicum AB (publ)

Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient's own immune system to fight cancer. The company's lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm www.immunicum.com

20181001_Immunicum_Info on Trading_ENG_Final



This announcement is distributed by West Corporation on behalf of West Corporation clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Immunicum AB via Globenewswire

Immunomedics (NASDAQ:IMMU)
Historical Stock Chart

1 Year : From Oct 2017 to Oct 2018

Click Here for more Immunomedics Charts.

Immunomedics (NASDAQ:IMMU)
Intraday Stock Chart

Today : Tuesday 16 October 2018

Click Here for more Immunomedics Charts.

Latest IMMU Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.